** Shares of drug developer CervoMed CRVO.O rise 4.4% to $6.44
** Brokerage Jones Research upgrades CRVO to "buy" rating from "hold", keeps PT of $15
** Upgrade follows CRVO's announcement of positive results from study of its drug, neflamapimod, in patients with dementia with Lewy bodies $(DLB)$ on Monday
** Data from study is boosting investor confidence, and we are seeing a more riskon approach heading into the next steps for netlamapimod in DLB patients - Jones Research
** DLB is a form of dementia caused by the accumulation of protein deposits called Lewy bodies in the brain's nerve cells
** Up to Wednesday's close, stock up 176.7% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.